Zentalis Pharmaceuticals (ZNTL) Stock Analysis

What Zentalis Pharmaceuticals does

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Key metrics

ETFs linked to ZNTL

Broad-market and Healthcare sector ETFs an investor holding Zentalis Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ZNTL fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals trades under the ticker ZNTL on NASDAQ.

Which exchange is ZNTL listed on?

ZNTL is listed on NASDAQ.

What sector does Zentalis Pharmaceuticals operate in?

Zentalis Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ZNTL in a portfolio?

PortView shows ZNTL's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.